MRSA (Methicillin-resistant Staphylococcus aureus)

Characteristics and resistance

Resistance in MRSA most commonly results from the mecA (or related mec) gene, which encodes an altered penicillin‑binding protein (PBP2a) with reduced affinity for beta-lactam antibiotics. The result is diminished effectiveness of penicillins and many cephalosporins. Detection of MRSA may be done by culture with antibiotic susceptibility testing or by molecular methods that identify mec genes directly.

Clinical presentation and diagnosis

MRSA can cause a spectrum of illness. Many infections are localized and cutaneous, but MRSA also causes surgical‑wound infections, pneumonia, bloodstream infections (bacteremia), and infections of bones, joints, or the urinary tract. Typical skin findings include pimples, boils, abscesses or areas of cellulitis that may be filled with pus. More severe disease can lead to sepsis or organ‑specific complications.

• Common signs: red, swollen, painful skin lesions; pus or drainage.
• Serious infections: fever, chills, shortness of breath, altered mental status, or signs of systemic illness.
• Diagnosis: bacterial culture with susceptibility testing; rapid molecular tests for mec genes and other resistance markers.

Treatment and prevention

Treatment depends on the site and severity of infection and on antibiotic susceptibility testing. For many skin infections, incision and drainage are critical and may be sufficient. When antibiotics are required, clinicians select agents active against the specific MRSA isolate; commonly used options include vancomycin, linezolid, daptomycin, and several oral agents for less severe disease. Choice of agent should be guided by laboratory testing and clinical context.

• Key preventive measures: hand hygiene, wound care, cleaning of contaminated surfaces, and appropriate use of contact precautions in healthcare settings.
• Decolonization (for example, topical nasal ointments and antiseptic body washes) is sometimes used in selected situations to reduce carriage.

History and public health impact

MRSA was first recognized shortly after the widespread clinical use of methicillin in the 1960s. Initially associated with healthcare environments (hospital‑associated MRSA, HA‑MRSA), distinct community‑associated strains (CA‑MRSA) emerged later and became notable causes of skin and soft tissue infections in otherwise healthy people. Because MRSA can be harder to treat and can spread in hospitals and communities, it remains a focus of infection control and antibiotic stewardship efforts.

Notable distinctions and practical points

Not all S. aureus are methicillin‑resistant; laboratory testing determines whether a given isolate is MRSA. The term "superbug" is sometimes applied in popular discussion to emphasize resistance, but clinical outcomes depend on timely recognition, appropriate therapy, and infection control. Surveillance, responsible antibiotic use, and simple preventive measures such as handwashing are central to limiting MRSA transmission.

For further reading and clinical guidance, see general resources linked below:

• MRSA overview and facts
• Clinical guidance on diagnosis
• Information on antibiotic resistance
• Antibiotic stewardship resources
• Patient advice on skin infections
• Infection control and prevention